ViroMed Receives US FDA Approval for Clinical Trial

ViroMed has announced that it has received an approval from the US Food and Drug Administration (FDA) for a Phase I/II trial for VM202-CAD. The heart disease medicine is being jointly developed with Biologics Delivery Systems Group, Cordis Corporation.

The trial will be for patients with angina pectoris and will take place at various medical centers designated by Cordis, such as Northwestern Memorial Hospital in Chicago and Minneapolis Heart Institute.